The non-alcoholic steatohepatitis (NASH) clinical development field is crowded with various players, targets and therapeutic approaches, but privately held Cirius Therapeutics Inc. thinks it may have a winner as its second-generation thiazolidinedione MSDC-0602K has shown ability to reduce liver enzymes and improve glycemic control with a good safety profile in a Phase IIb interim look.
Designed by Cirius co-founder and Vice President-R&D Jerry Colca to offer the insulin-sensitizing benefits of first-generation TZDs like Takeda...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
